COMPARISON OF ANALYSIS APPROACHES FOR PHASE III CLINICAL TRIALS IN AMYOTROPHIC LATERAL SCLEROSIS

被引:20
|
作者
Healy, Brian C. [1 ,2 ]
Schoenfeld, David [1 ,3 ]
机构
[1] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[2] Brigham & Womens Hosp, Partners MS Ctr, Brookline, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
amyotrophic lateral sclerosis; clinical trial; longitudinal analysis; sample size calculations; survival analysis; PLACEBO-CONTROLLED TRIAL; FUNCTIONAL RATING-SCALE; LONGITUDINAL DATA; ALS; MODELS; MULTICENTER;
D O I
10.1002/mus.23392
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: In this study we explore several methods for incorporating survival information in the analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scores. Methods: ALSFRS scores and patient survival times were simulated based on estimates from a recent clinical trial. Six analysis approaches were applied to the data. Each approach was based on ALSFRS scores, the survival time, or a combination of the 2. The power of each approach to detect potential treatment effects was estimated. Results: When the treatment acted solely on the change in ALSFRS, the shared parameter model provided the most power, although all of the models based on random effects were similar. As the effect on survival increased, rank-based analysis showed potential gains in power. Survival analysis was superior under a small effect on ALSFRS and a larger effect on mortality. Conclusions: The shared parameter model and rank-based approach can offer improvements in power over traditional approaches. Muscle Nerve 46: 506-511, 2012
引用
收藏
页码:506 / 511
页数:6
相关论文
共 50 条
  • [31] Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study
    Garcia-Gancedo, Luis
    Kelly, Madeline L.
    Lavrov, Arseniy
    Parr, Jim
    Hart, Rob
    Marsden, Rachael
    Turner, Martin R.
    Talbot, Kevin
    Chiwera, Theresa
    Shaw, Christopher E.
    Al-Chalabi, Ammar
    JMIR MHEALTH AND UHEALTH, 2019, 7 (12):
  • [32] Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials
    Gehr, Sinje
    Kaiser, Thomas
    Kreutz, Reinhold
    Ludwig, Wolf-Dieter
    Paul, Friedemann
    EPMA JOURNAL, 2019, 10 (04): : 425 - 436
  • [33] Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials
    Barp, Andrea
    Gerardi, Francesca
    Lizio, Andrea
    Sansone, Valeria Ada
    Lunetta, Christian
    EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (02) : 145 - 164
  • [34] Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
    Ortiz, Juan Fernando
    Khan, Sawleha Arshi
    Salem, Amr
    Lin, Zayar
    Iqbal, Zafar
    Jahan, Nusrat
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (10)
  • [35] A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis
    Beswick, Emily
    Park, Emily
    Wong, Charis
    Mehta, Arpan R.
    Dakin, Rachel
    Chandran, Siddharthan
    Newton, Judith
    Carson, Alan
    Abrahams, Sharon
    Pal, Suvankar
    JOURNAL OF NEUROLOGY, 2021, 268 (12) : 4510 - 4521
  • [36] Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms
    Kollewe, K.
    Dengler, R.
    Petri, S.
    NERVENARZT, 2008, 79 (06): : 653 - +
  • [37] Survival analysis of clinical and genetic factors in an amyotrophic lateral sclerosis cohort from China
    Cai, Zhengyi
    Liu, Qing
    Liu, Mingsheng
    Yang, Xunzhe
    Shen, Dongchao
    Sun, Xiaohan
    He, Di
    Zhang, Kang
    Shang, Liang
    Zhang, Xue
    Cui, Liying
    NEUROLOGICAL RESEARCH, 2022, 44 (07) : 651 - 658
  • [38] Changing amyotrophic lateral sclerosis diagnostic criteria: Will it impact clinical trials?
    Shefner, Jeremy M.
    MUSCLE & NERVE, 2022, 66 (04) : 377 - 379
  • [39] Neurophysiological measures in amyotrophic lateral sclerosis: Markers of progression in clinical trials
    de Carvalho, M
    Chio, A
    Dengler, R
    Hecht, M
    Weber, M
    Swash, M
    AMYOTROPHIC LATERAL SCLEROSIS, 2005, 6 (01): : 17 - 28
  • [40] Geographical distribution of clinical trials in amyotrophic lateral sclerosis: a scoping review
    Garcia-Parra, Beliu
    Guiu, Josep M.
    Povedano, Monica
    Marino, Eduardo L.
    Modamio, Pilar
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2024, 25 (3-4) : 376 - 381